Ustekinumab, a monoclonal antibody, is approved for the treatment of psoriasis vulgaris and psoriatic arthritis.

Biologic or targeted synthetic disease-modifying antirheumatic drugs (DMARDs) seem to be the most effective treatments for ...

Psoriatic arthritis (PsA) is an autoimmune disease ... Half received a 150 milligram (mg) shot of risankizumab at the start of the trial, one month later, and three months after that.

Sandoz announced the European launch of its Pyzchiva (ustekinumab) autoinjector. This is the first ustekinumab biosimilar in ...

HADLIMA™ (adalimumab-bwwd) injection, 40 mg/0.4 mL & 40 mg/0.8 mL is now interchangeable with all high- and low-concentration presentations ...

Biocon had entered into a settlement and licensing agreement with Janssen Biotech Inc, Janssen Sciences Ireland and Johnson & ...

After the launch of Ustekinumab, a biosimilar of Stelara, in the United States and Europe, Biocon Biologics’ biosimilar drug ...

Psoriatic arthritis was different ... They even help me take my medicine, which is an injection I give myself at home. They like to be in charge of setting up the supplies and counting down ...

Sandoz launches ustekinumab biosimilar, Pyzchiva autoinjector in Europe: Basel Saturday, May 24, 2025, 12:00 Hrs [IST] Sandoz, one of the global leaders in generic and biosimilar ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved guselkumab (Tremfya) for the treatment of Crohn’s ...

The U.K.’s Medicines and Healthcare products Regulatory Agency has approved guselkumab, or Tremfya, to treat Crohn’s disease ...

Pyzchiva® is a key biosimilar value driver for the Sandoz growth strategy. It has been launched in 23 markets in Europe. The autoinjector is now available in Spain and will continue to roll out across ...